Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 5/20 | 0.42 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.41 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20424079 | 0.80 | — | — | |
| SCHEMBL1963515 | 0.77 | CRBN (0.46) | CRBNOR51E2FKBP5KDM4ELMNA | |
| SCHEMBL13232100 | 0.74 | CRBN (0.42) | CRBNOR51E2FKBP5LMNAHSD17B10 | |
| SCHEMBL17037499 | 0.74 | CRBN (0.37) | CRBNOR51E2FKBP5KDM4EGAA | |
| SCHEMBL607485 | 0.71 | — | — | |
| SCHEMBL6920965 | 0.70 | CRBN (0.48) | CRBNOR51E2FKBP5KDM4EGAA | |
| SCHEMBL20374429 | 0.70 | OR51E2 (0.52) | CRBNOR51E2FKBP5KDM4ELMNA | |
| SCHEMBL21905938 | 0.68 | CRBN (0.46) | CRBNOR51E2FKBP5KDM4EGAA | |
| SCHEMBL12220286 | 0.68 | CYP11B1 (0.40) | LMNACYP2C9 | |
| SCHEMBL13262638 | 0.68 | CRBN (0.40) | CRBNOR51E2FKBP5KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586931-B2 | Triazolyl derivatives as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20150239866-A1 | TRIAZOLYL DERIVATIVES AS SYK INHIBITORS | MERCK CANADA INC. (CA) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239866-A1 | TRIAZOLYL DERIVATIVES AS SYK INHIBITORS | SYK, BTK, TYRO3 | CRBN 1022/4885OR51E2 3398/4885FKBP5 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.